Abstract P6-21-12: Local transdermal therapy (LTT): Drug permeation and distribution of telapristone acetate (TPA) in a pre-surgical window study of women undergoing mastectomy

Background: Low uptake and poor adherence to oral drugs for breast cancer prevention and ductal carcinoma in situ has led to an interest in local routes of delivery with the intent of decreasing systemic exposure and reducing toxicity. LTT has emerged as a possible alternative; previous studies have shown selectively higher concentrations in the breast than in the serum with this delivery route. A question related to LTT is whether or not the drug will permeate and distribute throughout the breast, as is expected with oral delivery.

Methods: We conducted a double-blind study of oral versus LTT delivery of the selective progesterone receptor modulator, telapristone acetate (TPA), in a presurgical window setting, enrolling 82 women planning therapeutic or prophylactic mastectomy. We randomized 67 women 1:1, to oral TPA 12 mg daily, or gel TPA applied to both breasts daily (12 mg/breast), for 4 weeks ±1 week. Mastectomy specimens were sampled at 5 non-tumor locations as well as the tumor and lymph node when available. Samples were split in two: drug concentration (conc.) assay using LC-MS/MS and histological evaluation of tissue composition (fat, fibrous stroma, epithelium). The primary endpoint was mean drug conc. across all breast locations (anticipating that the gel would deliver a mean concentration that was >50% of the mean in the oral group). A secondary endpoint was the drug distribution pattern across the breast, expecting that the distribution would be similar. The tumor sample was saved for biomarker assays related to TPA action; these are ongoing, for a pre-planned pooled analysis of data with NCT01800422 (reported in SABCS abstract 851863).

Results: Of 63 evaluable women (33 oral and 30 gel group), 27 had unilateral and 36 had bilateral mastectomy. The mean drug conc. in the oral group was 166.3 ng/G (SE 11.7), and in the gel group was 10.6 ng/G (SE 10.8), (p<.0001). The conc. was variable across the 7 locations tested in both groups. High concentrations were found in the superficial and deep central locations, retroareolar and lateral locations ranked in the middle, and the medial location was discrepant, being high in the oral and low in the gel group. The variation in drug concentration across all locations was not significantly different between groups (Kolmogorov-Smirnov p=0.99). Among women with bilateral mastectomy, drug concentrations were similar between breasts in both oral and gel groups. In the gel group, despite low TPA concentrations, there was evidence of drug metabolism. The major metabolite, CDB 4453 was detectable in 192/193 samples with detectable parent drug. Analysis of drug concentration adjusted for tissue composition is ongoing.

Conclusions: The gel formulation of TPA did not permeate the skin well. However, the drug delivered to the breast was distributed throughout the breast, similar to the oral delivery route, with the highest concentration in the deep central location. These drug distribution data are novel; drug distribution at multiple locations throughout the breast has not previously been shown. Further work is needed to understand breast distribution with formulations known to have good dermal permeation.

Citation Format: Lee O, Pilewskie M, Xu Y, Benante K, Blanco L, Helenowski I, Tull MB, Muzzio M, Jovanovic B, Karlan S, Hansen N, Bethke K, Kulkarni S, Perloff M, Dimond EP, Heckman-Stoddard BM, Khan SA. Local transdermal therapy (LTT): Drug permeation and distribution of telapristone acetate (TPA) in a pre-surgical window study of women undergoing mastectomy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-21-12.

Abstract OT1-04-01: A phase IIB pre-surgical trial of oral tamoxifen (TAM) versus transdermal 4-hydroxytamoxifen (4-OHT) in women with DCIS of the breast

Background

Ductal carcinoma in situ (DCIS) is diagnosed in 60,000 women annually in the US. TAM is proven to reduce risk of local recurrence and new primary breast cancer in women with estrogen receptor (ER) positive DCIS. However, acceptance of TAM has been low, primarily because of toxicity related to systemic exposure. Local delivery to the breast is an attractive alternative since low systemic levels could minimize toxicity. 4-OHT is an active metabolite of TAM. When formulated as a gel and applied to the breast skin, it is well tolerated, and results in 4-OHT breast tissue drug levels comparable oral TAM. In small pilot studies, its anti-proliferative effects on invasive breast tumors and DCIS are also similar to oral TAM [Lee O, et al. PMID 25028506]. The goal of our study is to validate these results in preparation for a Phase III trial of 4-OHT gel in comparison to oral TAM.

Methods

We are conducting a randomized, double-blinded, placebo-controlled, Phase IIB pre-surgical trial to demonstrate that daily application of 4-OHT gel will result in a reduction in the Ki-67 labeling index of DCIS lesions that is not inferior to that seen in women receiving daily oral TAM 20 mg daily. Ki-67 of the base-line diagnostic core needle biopsy will be compared to that of the therapeutic surgical excision sample after oral TAM or 4-OHT gel for 8 ± 2 weeks. Secondary endpoints include changes in Oncotype DCIS-Score, IHC markers (CD68, COX2, p16), hormone levels, coagulation markers, drug concentration in the plasma and breast tissue, the fraction of women with no residual DCIS in the surgical sample, and experienced symptoms. 100 women (assuming 20% non-evaluable samples or compliance issues) with DCIS (10% ER-positive) will be enrolled across six institutions into two intervention arms: oral TAM 20 mg daily, placebo gel and 4-OHT gel 4mg daily (2mg/breast), placebo capsule. All participants will be evaluable for toxicity from their first dose. All samples from all participants who receive drug will be evaluated and included in the primary analysis, which will be based on intent to treat principle. To date 15 of 100 participants have been enrolled across six institutions including: Northwestern University in Chicago, IL, St. Elizabeth Healthcare in Edgewood, KY, Duke University Medical Center in Durham, NC, Cleveland Clinic in Cleveland, OH, Memorial Sloan Kettering Cancer Center in New York, NY, and Mayo Clinic in Rochester, MN. Since study open, 69 potential participants have been contacted, 52 did not consent for screening, 17consented for screening, 2 are pending consent, and 15 have started study intervention. The most common reasons potential participants chose not to consent are wanting to schedule surgery as soon as possible, attitudes toward medical research, and current use of a prohibited concomitant medication such as a potent inhibitor of tamoxifen metabolism or exogenous sex steroid.

Funding Source: NCI Contract # HHSN2612201200035I.

Citation Format: Benante KA, Xu Y, Tull MB, Segura AJ, Alber KM, Kalinichenko K, Hou L, Jovanovic B, Perloff M, Heckman-Stoddard B, Dimond E, Khan SA. A phase IIB pre-surgical trial of oral tamoxifen (TAM) versus transdermal 4-hydroxytamoxifen (4-OHT) in women with DCIS of the breast [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-04-01.

Abstract P3-09-02: CRISPR-Cas9 mediated BRCA1 mutation in primary cells: Mutation efficiency and effects

Background: Germline mutations in Breast Cancer Associated (BRCA) 1 or 2 genes confer an increased risk of the development of breast and ovarian cancer. Germline mutation is followed by somatic loss of heterozygosity (LOH) resulting in biallelic inactivation. BRCA1 is involved in multiple homeostatic functions including control of chromatin organization, gene transcription, protein stability and cell division. Recent studies have demonstrated heterogeneity in LOH within and between premalignant and malignant breast tissues of BRCA1 mutation carriers. We hypothesize that LOH does not have a unitary effect on phenotype but differs by the function that is abrogated.

Methods: To test our hypothesis, we adopted CRISPR-Cas9 gene editing technology. The guide RNAs for targeting the exon sequence in the RING finger, nuclear export signal (NES), nuclear localization signal (NLS) and BRCA1 C Terminus (BRCT) domain/motif of BRCA1 were designed and synthesized. MCF10A cells were transfected with a complex of guide RNA and Cas9 protein (RNP) to cause in/del mutation. The mutation was analyzed by both T7E1 assay, and an innovative and more precise method developed in our lab that utilizes linked nucleic acids (LNA) and qPCR. Proliferation and apoptosis assays were performed using the transfected cells. Organoids prepared from BRCA1 mutation carriers also were transfected with RNPs and the mutation burden determined.

Results: Since single cell clones of the transfected MCF10A cells could not be selected and expanded, a pool of transfected cells was used for the analyses. T7E1 assay and qPCR analysis using LNAs demonstrated the presence of the mutations. A standard curve was created to enable the calculation of the mutation burden. IncuCyte analysis revealed increased proliferation and apoptosis, induced by irradiation, in cells with the mutation in Exon 10, where the extent of increase varied from 11% to 48% depending on the degree of mutation. In contrast, cells with the mutation in Exon 5 displayed diminished proliferation with no change in apoptosis. That mutations in exon10 and 5 have distinct biological effects when compared to the mutations in other exons is intriguing, and modification of binding proteins will be investigated. Organoids generated from BRCA1 mutation carriers (primary and nonmalignant cells) were able to be successfully transfected using the NEON electroporation system. Mutations were introduced by the CRISPR-Cas9 system and their extent quantified by our LNA-mediated qPCR method.

Conclusions: CRISPR-Cas9-mediated gene editing of BRCA1 in MCF10A resulted in a change in the proliferation rate and the extent of apoptosis that is dependent on the location of the de novo mutation within the gene. The development of a novel method, LNA-mediated qPCR, provides quantitative information regarding the mutations that may be used to correlate mutation burden with biological functional change. Successful establishment of this BRCA1 tumorigenesis model has provided us with a method to test other putative tumor suppressors.

Citation Format: Choi MR, Yadav S, Shidfar A, Khan SA, Clare SE. CRISPR-Cas9 mediated BRCA1 mutation in primary cells: Mutation efficiency and effects [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-09-02.

Abstract P3-06-06: Novel breast cancer mutational signatures

Background: Our understanding of the biological processes that generate somatic mutations in breast cancer has increased markedly over the past five years. Using the catalog of somatic mutations present in cancer genomes, over 30 “mutational signatures” have been produced. While these provide important insights into the processes responsible for somatic mutation, gaps remain, and the etiology of several signatures remains unknown.

Methods: We have developed a new method in which the specific nucleotide change (e.g., C>T), the codon that each mutation falls in (e.g., GCT), the position in the codon (e.g., 2), and the nucleotides immediately 5' and 3' of the mutation (e.g., 5': C; 3': G) are all considered. The summary of these mutation characteristics forms a mutational profile for each tissue sample. Putting multiple samples' profiles together forms a sparse matrix with the number of samples as rows and the mutation characteristics as columns. Nonsmooth nonnegative matrix factorization was then applied to enable the discovery of intrinsic patterns in this sparse matrix.

Results: Using somatic mutations identified in 1017 breast cancer tissues from The Cancer Genome Atlas (TCGA), we have identified four mutational signatures. Signature A correlates with the well-defined APOBEC signatures and signature B with the “aging” signature, which is the result 5-methylcytosine hydrolysis. Signature C and signature D are potentially new signatures. Signature D is enriched with C:G>A:T mutations; these mostly occur in the middle position of codons, and are enriched with GG(CC) either 5' or 3' of the mutation's sequence context. G>T mutations are known to occur as a consequence of oxidative damage that is not repaired. Guanines are vulnerable as they have the highest vertical oxidation potential of the nucleobases. The 5' guanines in GG sites are especially reactive. We hypothesize that Signature D results from oxidative mutagenesis.

When correlated with clinical phenotypes, the basal subtype is clearly enriched for tumors with the Signature D mutation pattern (exposure level is in 169 basal tumors and in 797 non-basal tumors, p=<0.01), suggesting an etiologic link with basal-like breast cancer. G>T somatic mutations in breast cancer mainly take place during cell replication rather than during transcription. In the normal breast, epithelial cell replication occurs during the luteal phase of the menstrual cycle and during pregnancy, primarily under the direction of progesterone (P). P binds to its receptor (PR) in a subpopulation of PR positive cells where it initiates the transcription of genes including RANKL, with resultant paracrine stimulation (through RANK), of the NF-κB signaling pathway in neighboring cells. The four RANKL genes (TOP2A, MKI67, PBK, CDK1), defined by Nolan et al., are all positively associated with the signature D (P-values < 0.05), suggesting that this type of mutagenesis is associated with RANKL pathway upregulation.

Conclusions: We have identified a potentially new somatic mutational signature, which we have designated as Signature D, which appears to result from exposure of DNA to oxidative stress during replication. It is associated with the basal subtype of breast cancer as well as RANKL- NF-κB pathway upregulation.

Citation Format: Zeng Z, Vo AH, Luo Y, Khan SA, Clare SE. Novel breast cancer mutational signatures [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-06-06.

Abstract P2-02-06: Deregulated lipid metabolism fuels the genesis of estrogen receptor negative breast cancer

Background:

There are no targeted pharmacologic interventions currently available for the prevention of hormone receptor negative breast cancer. Primary prevention with endocrine agents decreases the risk of ER positive disease with no effect against ER negative (ER-) disease. Thus, there is a compelling need to identify women at high risk for ER-negative breast cancer and to uncover the molecular mechanisms involved in its genesis. Our recent observation that a set of lipid metabolism (LiMe) genes are over-expressed in the contralateral unaffected breasts of women with unilateral ER- breast cancer suggests the novel hypothesis that specific lipid metabolism pathways in the breast produce a physiological milieu favoring the development of ER- breast cancer. We are now testing the specific hypothesis that lipids are the source of the acetyl-coA that is utilized to acetylate histones, an epigenetic modification that reprograms transcription.

Methods:

We developed an in-vitro model that relies on octanoic acid, a medium chain fatty acid that freely diffuses though the plasma and mitochondrial membranes. MCF-10A cells were plated and allowed to adhere overnight and then exposed to an increasing dose of sodium octanoate for 24 hours in complete media. Acetylation of Lysine 9 of Histone 3 (H3K9) was analyzed by Western blot and RNA was extracted for qPCR and RNA-seq. Chromatin packing density at the nanoscale was quantified bypartial wave spectroscopic (PWS) microscopy. Mammary organoids were prepared from breast tissue by collagenase digestion and similarly treated.

Results:

We found a striking, dose-dependent increase of H3K9 acetylation in octanoate treated MCF-10A cells. The acetylation is specific to the lipids as no acetylation was observed in cells treated with the same concentration of the alcohol 1,4-Cyclohexanedimethanol. RNA-Seq revealed the differential expression of LiMe genes together with a significant upregulation of Hedgehog and Notch signaling pathways. Individual genes from various pathways were further verified by qPCR which revealed, for example, a four-fold increase in SHH expression and 25-fold increase in DLL4. The expression of two of the previously identified LiMe genes, HMGCS2 and ACSL3, was increased four-fold in the octanoate treated MCF10A cells. We repeated the octanoate treatment in organoids and found similar effects. PWS in live cells showed a dose-dependent increase in chromatin packing scaling (D) in cells exposed to octanoate, suggesting that accessibility of chromatin to transcription factors is increased upon fatty acid treatment.

Conclusion:

A lipid rich microenvironment affects metabolism in ER- MCF10A cells and stimulates pro-neoplastic signaling via histone modifications. This supports our hypothesis that perturbed lipid metabolism plays an important role in the development of ER- breast cancer. Further mechanistic studies will determine if the genes differentially expressed in cell culture are also differentially expressed in antecedent benign breast biopsies from women eventually diagnosed with ER+ and ER- cancer.

Citation Format: Yadav S, Choi M, VanDerway D, Bauer G, Backman V, Khan SA, Clare SE. Deregulated lipid metabolism fuels the genesis of estrogen receptor negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-02-06.

Abstract P5-04-02: Progesterone receptor (PR) antagonism by telapristone acetate (TPA): A randomized, placebo-controlled phase IIB pre-surgical window trial in women with stage 0-II breast cancer

Background: In vitro and preclinical data indicate that TPA, a selective PR modulator, has activity against hormone-sensitive early breast cancer. We conducted a pre-surgical window trial of oral TPA in Stage 0-II breast cancer to assess the effect of TPA on suppression of cell proliferation (Ki67), and on differential gene expression in responsive and non-responsive tumors.

Methods: We enrolled 70 pre and postmenopausal women into a 1:1 randomized, double-blind, placebo-controlled trial of oral TPA 12mg (Repros Therapeutics Inc.) for 2-10 weeks. The primary endpoint was Ki67 labelling, comparing diagnostic core needle biopsy to post-therapy surgical specimens. Ki67 changes were quantitated by dual immunohistochemistry (Ki67/pan-cytokeratin) and image analysis (Aperio ImageScope and Definiens Tissue Studio®). RNA-sequencing (using RNA extracted from the paraffin blocks) was performed with Illumina TruSeq RNA Coding Access method. Differential gene expression pre-post therapy was assessed, followed by Gene Set Enrichment Analysis for pathway analysis. Ki67 changes from baseline were tested with Paired signed-rank test. For gene expression analysis, p values were calculated by Wald test and adjusted for multiple comparisons by Benjamini-Hochberg method (adjusted p <0.05 and 2-fold gene expression cut-off).

Results: Among 61 evaluable women, (29 placebo and 32 TPA) 97% of tumors were ER or PR positive and 91% were ER and PR positive (balanced across arms). A significant 6% decrease in mean %Ki67 was seen in the TPA arm (p= 0.003). When stratified by menopause, the significance held in premenopausal women (n= 22, p= 0.03) but not in postmenopausal women (n=10, p= 0.08). However, a Ki67 decrease (4%) was also observed in placebo group (p = 0.04); this was non-significant after pre- postmenopausal stratification. Overall, differential gene expression analysis showed no significant modulation of genes in either group. Using a pre-specified response parameter (50% relative reduction in Ki67), we identified 12/32 (38%) “responders” in the TPA, and 9/29 (31%) in the placebo arm. In sub-group analysis of these responders, we found 103 genes to be significantly modulated by treatment in the TPA “responders”, but saw no significant change in any gene expression in placebo “responders”. Gene set enrichment analysis for the 103 genes showed that TPA blocked the progression of cell cycle genes (PTTG1, PLK1, UBE2C, HIST1H3F, PSMD3, and etc.) and suppressed PGR and ERBB2 expression. In a pre-planned pooled analysis, these results will be combined with NCT02314156, reported in SABCS abstract 851790.

Conclusions: An anti-proliferative (Ki67) signal of TPA was observed in early stage breast cancer patients, but interpretation was limited by placebo group changes. The TPA group demonstrated differential suppression of proliferation-related genes among Ki67 responders, but the placebo group did not. Ongoing analysis will examine signatures related to stemness, metastasis, and immune suppression (potentially better endpoints in trials targeting P signaling). These analyses may help us select the right population and the right biomarkers for future trials.

Citation Format: Lee O, Sullivan ME, Xu Y, Shidfar A, Ivancic D, Zeng Z, Singhal H, Helenowski I, Jovanovic B, Hansen N, Bethke K, Gann P, Gradishar WJ, Clare SE, Khan SA. Progesterone receptor (PR) antagonism by telapristone acetate (TPA): A randomized, placebo-controlled phase IIB pre-surgical window trial in women with stage 0-II breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-02.

Facile synthesis of lanthanide doped yttria nanophosphors by a simple microplasma-assisted process

An environmentally friendly microplasma-based method is applied to produce crystalline lanthanide doped nanophosphors of controllable photoluminescence properties.

Oxidant free conversion of alcohols to nitriles over Ni-based catalysts

Ni-Based catalysts converting various primary alcohols to nitriles in high yields under oxidant-free, low temperature conditions.

Mesoscale triphasic flow reactors for metal catalyzed gas–liquid reactions

Design and operation of a mesoscale triphasic reactor for flow hydrogenations, capable of delivering kg per day productivity from a single channel.

Multi-color lasing in chemically open droplet cavities

In this paper, we demonstrate FRET-based multicolor lasing within chemically open droplet cavities that allow online modulation of the gain medium composition. To do this, we generated monodisperse microfluidic droplets loaded with coumarin 102 (donor), where the spherical droplets acted as whispering gallery mode (WGM) optical cavities in which coumarin 102 lasing (~ 470 nm) was observed. The lasing color was switched from blue to orange by the introduction of a second dye (acceptor, rhodamine 6 G) into the flowing droplet cavities; subsequent lasing from rhodamine 6 G (~ 590 nm) was observed together with the complete absence of coumarin 102 emission. The ability to control color switching online within the same droplet cavity enables sequential detection of multiple target molecules within or around the cavity. As a demonstration of this concept, we show how the presence of FITC-Dextran and methylene blue (MB) in the medium surrounding the lasing droplets can be sequentially detected by the blue and orange laser respectively. The method is simple and can be extended to a range of water-soluble dyes, thus enabling a wide spectral range for the lasing with the use of a single pump laser source.

Adiposity Results in Metabolic and Inflammation Differences in Premenopausal and Postmenopausal Women Consistent with the Difference in Breast Cancer Risk

Obesity is associated with increased risk of breast cancer in postmenopausal but not in premenopausal women. Many factors may be responsible for this difference. The aim of this study was to determine the mechanisms by which the genes related to the AMPK pathway, inflammation, and estrogen actions are affected by adiposity in breast tissue with the objective of identifying differences that may explain the different breast cancer risk in premenopausal and postmenopausal women. Random fine needle aspirates (rFNAs) of breast tissue were collected from 57 premenopausal and 55 postmenopausal women and were classified as normal weight, overweight, or obese. Expression levels of 21 target genes were determined using a TaqMan Low Density Array procedure. Breast tissue estradiol levels were measured by a liquid chromatography-tandem mass spectrometry procedure, and serum estradiol and follicle-stimulating hormone (FSH) were measured by a radioimmunoassay and an enzyme-linked immunosorbent assay, respectively. We found that in postmenopausal women, serum and tissue estradiol levels were increased in those who were overweight, and serum FSH levels were decreased in obese status. Interestingly, RPS6KB1, an AMPK downstream-responsive gene for protein synthesis and cell growth, and estrogen receptor α (encoded by the ESR1 gene) and its target gene GATA3 were significantly decreased in rFNA of premenopausal, obese women. In postmenopausal women, RPS6KB1, ESR1, and GATA3 expression remained unchanged in relation to adiposity. However, prostaglandin-endoperoxide synthase 2 (PTGS2), cyclin D1 (CCND1), and another ESR1 target gene, TFF1, were elevated in rFNA of obese postmenopausal women. Thus, as bodyweight increases, gene expression is indicative of increased proliferation in postmenopausal women but decreased proliferation in premenopausal women. Overall, our data reveal a novel process by which obesity promotes the risk of breast cancer in postmenopausal but not premenopausal women.

Irradiation-Induced Compositional Effects on Human Bone After Extracorporeal Therapy for Bone Sarcoma

The present study investigates Raman scattering of human bone irradiated with 50 Gy single dose during therapeutic treatment of Ewing and Osteosarcoma. Bone quality was evaluated via mineral-to-matrix ratio, degree of crystallinity, change in amount of calcium, and carbonate substitution. Alteration in collagen and its cross-links was quantified through second-derivative deconvolution of Amide I peak. A dose of 50 Gy radiation leads to almost 50% loss of mineral content, while maintaining mineral crystallinity, and small changes in carbonate substitution. Deconvolution of Amide I suggested modifications in collagen structure via increase in amount of enzymatic trivalent cross-linking (p < 0.05). Overall irradiation led to detrimental effect on bone quality via changes in its composition, consequently reducing its elastic modulus with increased plasticity. The study thus quantifies effect of single-dose 50 Gy radiation on human bone, which in turn is necessary for designing improved radiation dosage during ECRT and for better understanding post-operative care.

Clinicopathological Study of Enterocutaneous Fistula in Mymensingh Medical College Hospital

Enterocutaneous fistulae are a major catastrophe to the patients and surgeons and it still has high incidence of morbidity and mortality and their management remains a big challenge. Enterocutaneous fistula presents the surgeon with challenges of metabolic disorders and extensive sepsis. Total management of an intestinal fistula requires skill in nutritional support, stoma therapy, elimination of sepsis, well timed and well carried out surgery. Postoperative enterocutaneous fistulae account for approximately 80% of enterocutaneous fistulae. The majority of the intestinal fistula (75-85%) is iatrogenic occurring in the postoperative period following anastomotic dehiscence. They arise following emergency abdominal surgery for intestinal obstruction, inflammatory bowel disease or cancers. Protein calorie malnutrition alters the patients immune response, inflammatory reactions and tissue regenerations, all of which are essential for wound repair. The present study is an effort to highlight the incidence of enterocutaneous fistula after emergency and elective resection and anastomosis of gut with discussion over recent trends and developments in its management and compare with other studies. Objectives of the study are to determine the various clinicopathological features and management protocol of enterocutaneous fistula. There are recent advances in nutritional support. This descriptive type of cross-sectional study was carried out in the Department of Surgery, Mymensingh Medical College and Hospital, Mymensingh, Bangladesh from October 2010 to September 2011. Total 42 cases of enterocutaneous fistulae were selected purposively. Enterocutaneous fistulae are more common in patients of low economic condition. Enterocutaneous fistulae are more common after emergency abdominal surgery. Spontaneous closure occurred in 17(40.48%) cases and surgery needed in 25(59.52%) cases. Of them 20(80.00%) were healed and 5(20.00%) were expired. In spite of improvement in the management protocol of enterocutaneous fistula, there is still high unacceptable morbidity and mortality rate. Total parenteral nutrition (TPN) is not available and very costly, and health care facilities are also limited in our country. Patients with enterocutaneous fistula require fluid, electrolytes and nutritional support. Anaemia, dehydration, electrolytes imbalance should be corrected prior to abdominal surgery if possible. Surgical treatment for enterocutaneous fistula should be performed only after failure of conservative treatment of more than 12 weeks.

Electrically controlled mass transport into microfluidic droplets from nanodroplet carriers with application in controlled nanoparticle flow synthesis

Microfluidic droplets have been applied extensively as reaction vessels in a wide variety of chemical and biological applications. Typically, once the droplets are formed in a flow channel, it is a challenge to add new chemicals to the droplets for subsequent reactions in applications involving multiple processing steps. Here, we present a novel and versatile method that employs a high strength alternating electrical field to tunably transfer chemicals into microfluidic droplets using nanodroplets as chemical carriers. We show that the use of both continuous and cyclic burst square wave signals enables extremely sensitive control over the total amount of chemical added and, equally importantly, the rate of addition of the chemical from the nanodroplet carriers to the microfluidic droplets. An a priori theoretical model was developed to model the mass transport process under the convection-controlled scenario and compared with experimental results. We demonstrate an application of this method in the controlled preparation of gold nanoparticles by reducing chloroauric acid pre-loaded in microfluidic droplets with l-ascorbic acid supplied from miniemulsion nanodroplets. Under different field strengths, l-ascorbic acid is supplied in controllable quantities and addition rates, rendering the particle size and size distribution tunable. Finally, this method also enables multistep synthesis by the stepwise supply of miniemulsions containing different chemical species. We highlight this with a first report of a three-step Au-Pd core-shell nanoparticle synthesis under continuous flow conditions.

Is VEGF under-expressed in Indian children with Perthes disease?

BACKGROUND

The role of vascular endothelial growth factor (VEGF) after ischaemic necrosis of the femoral head in Legg-Calve-Perthes disease (LCPD) has not been adequately studied in humans, especially in Indian population. Therefore, we aimed to evaluate the serum levels of VEGF-A in Indian children with various stages of LCPD and compare them with those of an age- and sex-matched control group of healthy children.

METHODS

In this case-control study, we enrolled 42 children (below 14 years age) suffering from LCPD and 21 age- and sex-matched healthy controls. Patients were classified radiographically according to Waldenstrom's classification. Serum VEGF-A was estimated by sandwich enzyme-linked immunosorbent assay technique. The serum values were compared between the patient group and the control group, as well as between the Waldenstrom subgroups. Results were expressed as means with ranges or median with interquartile range.

RESULTS

The mean age in the patient as well as the control group was 9 years (range 4-13 years). The median value (interquartile range) of serum VEGF-A was 162.5 pg/ml (673.75 pg/ml) in the patient group and 652 pg/ml (190.5 pg/ml) in the control group (p = 0.013). When compared between lower Waldenstrom stages (initial stage + stage of fragmentation) and higher Waldenstrom stages (re-ossification stage + stage of healing), the mean values of serum VEGF-A were 464.7 pg/ml (range 0-2211 pg/ml) and 301.1 pg/ml (range 0-1910 pg/ml), respectively (p = 0.305).

CONCLUSIONS

VEGF is under-expressed in Indian children suffering from LCPD. As VEGF acts as a key regulator of endochondral ossification, our finding may open new therapeutic approaches to the disease. Also, serum VEGF may act as a valuable marker for the follow-up of the disease. Our study also provides baseline data about serum VEGF-A levels in Indian cohort of LCPD patients. Future multi-centre studies are warranted with a larger sample size to fully appreciate the patho-physiological changes in VEGF occurring in LCPD.

D-Meson Azimuthal Anisotropy in Midcentral Pb-Pb Collisions at sqrt[s]_{NN}=5.02 TeV

The azimuthal anisotropy coefficient v_{2} of prompt D^{0}, D^{+}, D^{*+}, and D_{s}^{+} mesons was measured in midcentral (30%-50% centrality class) Pb-Pb collisions at a center-of-mass energy per nucleon pair sqrt[s_{NN}]=5.02  TeV, with the ALICE detector at the LHC. The D mesons were reconstructed via their hadronic decays at midrapidity, |y|<0.8, in the transverse momentum interval 1<p_{T}<24  GeV/c. The measured D-meson v_{2} has similar values as that of charged pions. The D_{s}^{+} v_{2}, measured for the first time, is found to be compatible with that of nonstrange D mesons. The measurements are compared with theoretical calculations of charm-quark transport in a hydrodynamically expanding medium and have the potential to constrain medium parameters.

First report of Chikungunya virus circulation during a dengue outbreak in Arunachal Pradesh, a Northeastern state of India

Dengue has become a major public health problem in Pasighat, Arunachal Pradesh since 2012 outbreak. This region is rich in Aedes mosquitoes, the common vector for Dengue and Chikungunya (CHIK), however, active surveillance of CHIK is lacking in this part of India. Therefore, this study has been undertaken to detect the presence of CHIKV infection during 2014 and 2015 dengue outbreak in Arunachal Pradesh. A total of 116 (52 during 2014 and 64 during 2015 outbreak) dengue negative serum samples were collected from General Hospital, Pasighat and were screened for the presence of CHIK IgM antibodies. All the samples were further processed for CHIKV RNA detection by RT-PCR using specific primers. Phylogenetic tree was constructed by Neighbor Joining method using Kimura-2 parameter model. A total of 8 samples were found to be positive for IgM antibodies. RT-PCR showed CHIKV RNA positivity in 2 samples. Both of these samples belonged to 2014 outbreak. Phylogenetic tree revealed that the CHIKV circulating during the outbreak belonged to Eastern, Central and Southern African genotype. Sequence analysis showed two uniform nucleotide substitutions. Circulation of CHIKV masked by dengue is reported from this study. Therefore, CHIKV diagnosis should be made as a routine test in areas where dengue is already endemic so as to prevent misdiagnosis of the disease and to check its accomplishment before commencing an outbreak.

Abstract P6-07-09: Attenuation of progesterone driven mammary stem cell expansion by telapristone acetate

Purpose: The interplay of the ovarian hormones estradiol (E2) and progesterone (P4) contributes to the development of breast cancer, potentially aided by P4-induced expansion in mammary stem cells as observed in diestrous phase in mice, as well as the luteal phase and during pregnancy in women. Telapristone Acetate (TPA), a selective progesterone receptor modulator (SPRM), exhibits a protective effect against mammary carcinogenesis in rodents. TPA has been shown to display a more specific PR blockade and less toxicity when compared to RU486. We have examined the mammary stem cell pool expansion upon exposure to E2+P4 in mice and compared its attenuation by both TPA and RU486.

Methods: 8 week old female ovariectomized FVB mice weighing above 20g, were randomized into 4 treatment groups: sham (skin incision only, no pellets), E2+P4, E2+P4+Telapristone Acetate (TPA), E2P4+ Mifepristone (RU486). Eight experimental replicates were performed. At age 10 weeks, the mice were implanted with subcutaneous 30-day release pellets of E2 and P4 (0.3 mg E2 & 30.0 mg P4), E2P4+TPA (30.0 mg) and E2P4+RU486 (30.3 mg) in either flank. The mice were euthanized at day 15 of treatment. Single cell suspensions of the 4th inguinal mammary gland pair and one thoracic gland were prepared and labeled with cell surface markers. Lineage negative mammary gland cells were sorted into luminal and basal population subsets. The basal cell niche was identified as CD24+CD49fhi, the mammary stem cells (MaSC) within this niche are identified by CD61+CD49fhi. The cells were sorted on BD FACSAria 5-Laser and the data was analyzed using BD FACSDIVA.The D'Agostino-Pearson test was performed to determine the normal distribution and once normal distribution was confirmed one-way ANOVA (repeated measures) was performed to examine differences in percent cell populations with Tukey test for post-hoc analysis.

Results: The mammary stem cells (MaSC, CD61+CD49fhi) within the basal cell (CD24+CD49fhi) niche showed significant expansion at day 15 in mice implanted with Estrogen and Progesterone 30-day release pellet compared to sham (64.2%, 45.07% respectively; p=0.0392). This expansion was significantly attenuated in both TPA (-38.21%, p=0.011) and RU486 (-34.30%, p=0.002) treated mice compared to MaSC in mice treated with E2+P4 alone (+45.07%). Simultaneously, luminal progenitor cells (CD61+CD49flo) show a marked reduction in E2+P4 treated mice compared to sham (17.77%, 45.54%, respectively; p=0.0375). Luminal mature cells (CD61-CD49flo) show an expansion in E2+P4 treated mice compared to sham (82.23%, 54.41% respectively; %, p=0.0371). TPA significantly (58.40 %, p=0.061) suppresses LM cells expansion observed in the E2+P4 group. TPA and RU486 show significant suppression of the MaSC population in mouse mammary gland compared to the EP-treated mice.

Conclusion: TPA and RU486 alter the P4 driven changes in mammary gland cellular composition and in a manner consistent with the hypothesis that they will inhibit hormone-induced tumorigenesis in the mammary gland. To gain a better insight into this phenomenon, a high throughput transcriptomic profiling (RNASeq) of mammary stem cells isolated from the treatment groups is being performed.

Citation Format: Ranjan M, Lee O, Sun L, Karavites L, Clare S, Khan SA. Attenuation of progesterone driven mammary stem cell expansion by telapristone acetate [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-07-09.

Abstract P5-14-01: Telapristone acetate abrogates PR-dependent paracrine-mediated mammary cell proliferation

Background: Blockade of the progesterone (P)-progesterone receptor (PR) axis is a novel but untested strategy for breast cancer prevention. We report preclinical data evaluating telapristone acetate (TPA) compared with mifepristone (MFP), the prototype PR-antagonist. We hypothesize that the progesterone-PR blockade by TPA will inhibit PR-dependent paracrine expression (RANKL, WNT4, ID4, and calcitonin) attenuating cell proliferation and abrogating side branching and alveoli formation of mammary glands induced by hormones similar in extent or superior to MFP.

Methods:Adult virgin FVB mice at 12 weeks of age were randomized to four treatment groups: no treatment control, EP (0.3 mg E + 30 mg P), EP + TPA (30mg), and EP + MFP (30mg). Hormone and drug pellets were subcutaneously implanted in flank area between the neck and shoulder. After 28-day treatments, the mice were euthanized to collect mammary glands, and processed as mammary whole mounts and as formalin-fixed paraffin embedding (FFPE) specimens. We evaluated cell proliferation (Ki67) by immunohistochemistry. Total RNA was extracted from FFPE specimens and the Nanostring nCounter assay was utilized to assess paracrine gene expression. The Mann Whitney test was used to calculate statistical significance (p&lt;0.05).

Results: We observed a considerable increase in side branches and alveoli in EP treatment group compared to the controls. The growth of the mammary gland stimulated by EP treatment was corroborated by a significant increase in Ki67 compared to control mice (median 41% vs 24%, respectively, p &lt; 0.0001). Both TPA and MFP treatment abrogated side branching and alveoli formation and significantly reduced median Ki67 to 1/3 of that of control mice having endogenous estrus cycle hormone levels (24%, 8%, and 9% for control, EP+TPA and EP+MFP groups, respectively).TPA induced greater Ki67 reduction than MFP (7.5 ± 1.9% vs. 9.4 ± 1.9%, p= 0.04). As expected, EP treatment upregulated the RANKL expression compared to the control group while the administration of TPA and MFP significantly inhibited the RANKL expression stimulated by EP treatment. The mRNA expression measurement revealed that Rankl expression was 18 fold increased by EP treatment but completely inhibited by TPA and MFP treatment (p&lt;0.001 for both drugs). Similarly the Rank expression was increased two-fold by EP treatment (p&lt; 0.05) but down-regulated by TPA and MFP treatment (p&lt;0.01 for both drugs). We observed significant upregulation of Wnt4, and Calca expression by EP treatment compared to controls (p&lt;0.01 for both). Id4 expression showed the same trend but the change was non-significant. The addition of TPA completely opposed the hormone-stimulated increase of three paracrine molecules (Wnt4, Calca, and Id4) to a level below control group (p&lt; 0.001 for all).

Conclusions: We have demonstrated that TPA abrogates cell proliferation induced by exogenous EP hormones in an ovary intact mouse model. The blockade of PR-P binding was evident by complete inhibition of paracrine expression (not only RANKL/RANK expression but also WNT4, Calcitonin, and ID4 expression). TPA was efficacious as MFP in opposing paracrine-induced mammary cell proliferation, and warrants further testing in a breast cancer prevention trial.

Citation Format: Lee O, Sun L, Karavites LC, Clare SE, Khan SA. Telapristone acetate abrogates PR-dependent paracrine-mediated mammary cell proliferation [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-14-01.

Abstract ES11-2: Local therapy of limited disease in ABC: what is the evidence?

Surgery and radiotherapy have been used as adjunctive treatments for women with Stage IV breast cancer and a low volume of disease, for many years. This encompasses patients with intact or recurrent disease at the primary site, as well as those with oligometastatic distant disease. The evidence to support local therapy (LT) approaches in this group of patients is largely retrospective, although randomized trials are ongoing. For patients with an intact primary tumor, over 20 retrospective analyses suggest that women undergoing primary site LT (PSLT) experience longer survival than those whose primary tumor receives no LT, with one meta-analysis of these data reporting a hazard ratio (HR) of 0.69 (95%CI 0.63, 0.77). However, a concern about selection bias as the explanation for this apparent benefit has led to several randomized trials. Two of these were reported recently, with mixed results. The design and the results of the two completed trials were different. In Mumbai, India (NCT00193778), initial therapy consisted of chemotherapy followed by randomization to PSLT or not; results showed no overall survival difference, but local control was improved in the PSLT arm. In Turkey, MF07-01 randomized Stage IV patients to PSLT or not, followed by usual systemic therapy; results suggest an improvement in overall survival at 5 years for women in the PSLT arm. Two other randomized trials are ongoing, both designed with initial systemic therapy. In the meantime, existing data do not clearly support the use of PSLT as a means of improved survival, but the local control advantage was clear in both trials, and therefore PSLT may be offered to women whose primary tumors do not respond well to systemic therapy.

For women with oligometastatic disease, the data supporting LT measures is again retrospective, and consists of small, highly selected series. However, interest in LT approaches spans back many decades, and studies suggest that various strategies of surgery, radiotherapy, and more recently stereotactic body radiotherapy (SBRT), are associated with prolonged survival. The distant sites that have been subjected to these approaches include isolated metastases in lung, liver, bone, and brain. For isolated lung lesions in particular, resection also allows a clear distinction between primary and metastatic disease, since a large fraction of solitary lung lesions may in fact be primary lung tumors. In the liver, small retrospective series of highly selected patients undergoing resection suggest that longer-than-expected median survival can be observed in patients with limited disease and a long disease-free interval. Minimally invasive ablation techniques are being used with similar intent. For osseous sites, retrospective analyses of high-dose radiotherapy with ablative intent reflect similar caveats and similar results to the data on lung and liver. An important ongoing trial (NCT02364557) is randomizing women with a controlled primary tumor site and ≤2 metastatic lesions that are amenable to treatment with SBRT or surgery, to usual care or usual care with the addition LT to distant sites that must be separated by a distance of &gt;5 cm. These ongoing studies will bring much-needed clarity to the role pf LT approaches to both the primary site and limited distant disease.

Citation Format: Khan SA. Local therapy of limited disease in ABC: what is the evidence? [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr ES11-2.